Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates

References

• Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad, II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997–2004. Eur J Clin Microbiol Infect Dis 2007; 26:13–20.
   PubMed Web of Science ®Google Scholar
• Ansari SR, Hanna H, Hachem R, Jiang Y, Rolston K, Raad I. Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer. Cancer 2007;109:2615–22.
   PubMed Web of Science ®Google Scholar
• Crum NF, Utz GC, Wallace MR. Stenotrophomonas maltophilia endocarditis. Scand J Infect Dis 2002;34:925–7.
   PubMed Web of Science ®Google Scholar
• Hanes SD, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, . Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002;35:228–35.
   PubMed Web of Science ®Google Scholar
• Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP, . Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004;37:350–8.
   PubMedGoogle Scholar
• Leroy O, d’Escrivan T, Devos P, Dubreuil L, Kipnis E, Georges H. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms. Infection 2005;33:129–35.
   PubMed Web of Science ®Google Scholar
• Tsai WP, Chen CL, Ko WC, Pan SC. Stenotrophomonas maltophilia bacteremia in burn patients. Burns 2006; 32:155–8.
   PubMed Web of Science ®Google Scholar
• Tzanetou K, Triantaphillis G, Tsoutsos D, Petropoulou D, Ganteris G, Malamou-Lada E, . Stenotrophomonas maltophilia peritonitis in CAPD patients: susceptibility to antibiotics and treatment outcome: a report of five cases. Perit Dial Int 2004;24:401–4.
   PubMed Web of Science ®Google Scholar
• Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection 2010; 38:211–5.
   PubMed Web of Science ®Google Scholar
• Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002;34:1653–6.
   PubMed Web of Science ®Google Scholar
• Nseir S, Di Pompeo C, Brisson H, Dewavrin F, Tissier S, Diarra M, . Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care 2006;10:R143.
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis 2001;32(Suppl 2):S104–13.
   Google Scholar
• Zhang L, Li XZ, Poole K. SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001;45: 3497–503.
   PubMed Web of Science ®Google Scholar
• Mercuri PS, Ishii Y, Ma L, Rossolini GM, Luzzaro F, Amicosante G, . Clonal diversity and metallo-beta- lactamase production in clinical isolates of Stenotrophomonas maltophilia. Microb Drug Resist 2002l;8:193–200.
   PubMed Web of Science ®Google Scholar
• Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007;26:229–37.
   PubMed Web of Science ®Google Scholar
• Al-Jasser AM. Stenotrophomonas maltophilia resistant to trimethoprim–sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 2006;5:23.
   PubMedGoogle Scholar
• Barbolla R, Catalano M, Orman BE, Famiglietti A, Vay C, Smayevsky J, . Class 1 integrons increase trimethoprim–sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob Agents Chemother 2004;48:666–9.
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010;54:2735–7.
   PubMed Web of Science ®Google Scholar
• Gulmez D, Cakar A, Sener B, Karakaya J, Hascelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 2010;16:322–8.
   PubMed Web of Science ®Google Scholar
• Visalli MA, Jacobs MR, Appelbaum PC. Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1998;42:2002–5.
   PubMed Web of Science ®Google Scholar
• White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time–kill, checkerboard, and E test. Antimicrob Agents Chemother 1996;40:1914–8.
   PubMed Web of Science ®Google Scholar
• Zelenitsky SA, Iacovides H, Ariano RE, Harding GK. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2005; 51:39–43.
   PubMed Web of Science ®Google Scholar
• Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006;19: 155–61.
   PubMedGoogle Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty second informational supplement. M100–S22. Wayne, PA: CLSI; 2012.
   Google Scholar
• Gales AC, Jones RN, Andrade SS, Pereira AS, Sader HS. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis 2005;9:348–56.
   PubMedGoogle Scholar
• Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbarth S. Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim–sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000;32:651–6.
   PubMedGoogle Scholar